ANDA 206726, held by Aurolife Pharma. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 206726 (Methylphenidate Hydrochloride), held by Aurolife Pharma, was first approved by FDA on Oct 21, 2016, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 21, 2016 | Original application | Approved | None posted |
| Methylphenidate Hydrochloride18MG ยท tablet, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride27MG ยท tablet, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride36MG ยท tablet, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride54MG ยท tablet, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Sep 20, 2022 | Supplement 5Labeling ยท Standard review | Approved | None posted |
| Aug 7, 2020 | Supplement 1Labeling ยท Standard review | Approved | None posted |
| Oct 21, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters